GMTX vs. JAZZ, BPMC, VKTX, IONS, SMMT, CYTK, OGN, NUVL, MDGL, and BBIO
Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Summit Therapeutics (SMMT), Cytokinetics (CYTK), Organon & Co. (OGN), Nuvalent (NUVL), Madrigal Pharmaceuticals (MDGL), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Gemini Therapeutics (NASDAQ:GMTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.
89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 4.4% of Jazz Pharmaceuticals shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Jazz Pharmaceuticals currently has a consensus price target of $190.92, indicating a potential upside of 70.39%. Given Gemini Therapeutics' higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Gemini Therapeutics.
In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 12 mentions for Jazz Pharmaceuticals and 0 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.77 beat Jazz Pharmaceuticals' score of 0.00 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.
Jazz Pharmaceuticals received 1080 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 80.57% of users gave Jazz Pharmaceuticals an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Jazz Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500.
Jazz Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals has a net margin of 8.61% compared to Jazz Pharmaceuticals' net margin of 0.00%. Gemini Therapeutics' return on equity of 27.86% beat Jazz Pharmaceuticals' return on equity.
Summary
Jazz Pharmaceuticals beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.
Get Gemini Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemini Therapeutics Competitors List
Related Companies and Tools
